Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:EMCNASDAQ:NEPTNASDAQ:ORPHNASDAQ:VINC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$25.87+0.8%$0.00$22.99▼$29.13N/AN/A13.90 million shs14,706 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsVINCVincerx Pharma$0.73-18.9%$4.07$0.61▼$9.37$19.20M1.11.26 million shs1.72 million shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC+0.23%+2.02%-1.31%+3.14%-11.67%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-55.36%-99.22%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%VINCVincerx Pharma-3.58%-0.37%-82.49%-22.70%-29.95%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMCEMC0.5977 of 5 stars0.04.01.70.00.01.70.7NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/AVINCVincerx Pharma1.5802 of 5 stars3.52.00.00.01.52.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMCEMCN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AVINCVincerx Pharma3.00Buy$5.00584.93% UpsideCurrent Analyst RatingsLatest EMC, ARIX, ORPH, VINC, and NEPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/1/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMCEMCN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00ORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/AVINCVincerx PharmaN/AN/AN/AN/A$0.52 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMCEMCN/A$2.0512.62∞N/AN/AN/AN/AN/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/AVINCVincerx Pharma-$40.16M-$1.89N/AN/AN/AN/A-187.73%-126.26%5/9/2024 (Estimated)Latest EMC, ARIX, ORPH, VINC, and NEPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023VINCVincerx PharmaN/A-$0.23-$0.23-$0.23N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMCEMC$0.461.78%N/A22.44%N/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMCEMCN/AN/AN/ANEPTNeptune Wellness SolutionsN/A0.230.10ORPHOrphazyme A/S0.141.80N/AVINCVincerx PharmaN/A2.632.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMCEMC79.86%NEPTNeptune Wellness Solutions14.44%ORPHOrphazyme A/S10.74%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipEMCEMC0.40%NEPTNeptune Wellness Solutions5.10%ORPHOrphazyme A/SN/AVINCVincerx Pharma20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMCEMCN/AN/AN/ANot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableVINCVincerx Pharma4121.41 million17.00 millionNot OptionableEMC, ARIX, ORPH, VINC, and NEPT HeadlinesSourceHeadlineWhy Vincerx Pharma (VINC) Stock Is Fallingmsn.com - April 26 at 8:27 PMVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrantsglobenewswire.com - April 26 at 12:27 AMVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrantsglobenewswire.com - April 25 at 4:01 PMVincerx Pharma, Inc. Common Stock (VINC)nasdaq.com - April 23 at 2:06 AMAACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survivalfiercebiotech.com - April 18 at 12:36 PMAnalyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)americanbankingnews.com - April 16 at 2:40 AMAgendia’s BluePrint Included in German Oncology Group Guidelinesfinance.yahoo.com - April 12 at 9:45 AMVaccines, Next-Gen Approaches Target the Toughest Cancers: AACRbiospace.com - April 12 at 9:45 AMThe Rise of Zyn: The Oral Nicotine Product Going Viralfinance.yahoo.com - April 10 at 4:08 PMVincerx Pharma Inc (VINC) Gets a Buy from Leerink Partnersmarkets.businessinsider.com - April 10 at 9:44 AMVincerx (VINC) Tumbles on Results From Cancer Therapy Studyzacks.com - April 9 at 2:36 PMACOR, HUBC and DATS among pre-market losersmsn.com - April 9 at 9:19 AMVincerx in selloff after early-stage data for cancer therapymsn.com - April 9 at 9:19 AMCantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)marketbeat.com - April 9 at 8:49 AMWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?investorplace.com - April 9 at 8:40 AMVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - April 8 at 4:30 PMFY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)marketbeat.com - April 4 at 9:13 AMQ1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink Partnrsmarketbeat.com - April 3 at 6:00 AMVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023investorplace.com - April 2 at 8:06 AMVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatefinanznachrichten.de - April 1 at 4:30 PMVincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgeraldmarketbeat.com - April 1 at 12:23 PMVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024finance.yahoo.com - April 1 at 10:47 AMVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Lookfinance.yahoo.com - March 29 at 8:49 PMVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024marketwatch.com - March 29 at 3:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Intuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery MovementAll Headlines Company DescriptionsEMCNYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Orphazyme A/SNASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Vincerx PharmaNASDAQ:VINCVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.